OTC$PTN

Palatin Technologies Inc · Q3 2024 earnings

Q3 2024 earnings · · Investor relations

Briefing

Palatin Technologies reported financial results for the third quarter of fiscal year 2024 and provided a corporate update.

Palatin Technologies reported a net loss of $8.4 million, or $(0.53) per common share, for the quarter ended March 31, 2024. They had no product revenue due to the sale of Vyleesi. Cash, cash equivalents, and marketable securities totaled $10.0 million as of March 31, 2024.

  • Phase 3 MELODY-1 clinical trial for DED demonstrated that PL9643 has the potential to be a highly differentiated product.
  • Study results showed statistically significant efficacy for the co-primary symptom endpoint of pain and 7 of 11 exploratory secondary endpoints, including eye dryness.
  • The company is advancing discussions with potential collaboration partners and actively preparing for a meeting with the FDA to discuss the remaining studies for the PL9643 program.
  • Two new therapeutic area clinical trials are expected to launch in the second quarter of calendar year 2024.

Headline financials

Total Revenue

$0.00

Previous: $1.2M-100.0%
EPS (adj)

$15.00

Previous: -$0.63+2481.0%
Capital Expenditures

-$37.6K

Previous: -$382K+90.1%
Free Cash Flow

-$25M

Previous: -$19.2M-30.4%
Net Income

-$8.44M

Previous: -$7.15M-18.0%
Operating Income

-$9.22M

Previous: -$7.3M-26.3%
Gross Profit

$0.00

Previous: $1.2M-100.0%
Cash & Equivalents

$21.5M

Previous: $19.6M+9.4%
Total Assets

$11.4M

Previous: $25.6M-55.5%
R&D Expense

$7.16M

No prior period

Revenue & EPS history

Palatin Technologies · Revenue · Quarterly

$0

Q3 2024-100%vs Q3 2023
Beat estimate in 4 of 10 quarters(40%)
ActualEstimate

Forward guidance

Palatin believes that existing cash, cash equivalents, marketable securities and accounts receivable, will be sufficient to fund currently anticipated operating expenses and disbursements into the second half of calendar year 2024.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2024

Historical avgQ3 2024

-2.4%

Avg return

Earnings day

-0.6%

Avg return

5 days after

-2.5%

Avg return

30 days after

31%

20 / 64 earnings

Positive

+36.4%

Q3 2026

Best reaction

-27.1%

Q2 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026+1.2%+29.2%+18.2%
Q1 2026+0.0%+27.8%+152.3%
Q3 2026+36.4%+9.1%-9.1%
Q3 2025+22.2%+55.6%+11.1%
Q2 2025+7.1%+4.0%-20.2%
Q1 2025-21.5%-21.8%-26.1%
Q4 2024-8.3%-1.1%+39.3%
Q3 2024-15.4%-15.4%-24.5%
Q2 2024-27.1%-21.7%-62.8%
Q1 2024-1.0%-2.5%+31.3%
Q4 2023-8.5%+19.7%+13.3%
Q3 2023-5.8%-3.1%-13.9%
Q2 2023-8.8%-2.2%-18.0%
Q1 2023-9.0%-5.8%-25.7%
Q4 2022-19.5%-27.7%-43.6%
Q3 2022-7.7%-10.3%-28.2%
Q2 2022+5.0%+0.0%+2.5%
Q1 2022-2.5%-10.0%+35.0%
Q4 2021-6.4%-8.5%-12.8%
Q3 2021+9.8%+13.4%+10.4%
Q2 2021-19.5%-23.9%-33.6%
Q1 2021+7.3%+2.4%+4.9%
Q4 2020+0.0%-4.2%-20.8%
Q3 2020-2.2%-2.2%+30.4%
Q2 2020-14.1%-18.3%-39.4%
Q1 2020-4.9%-2.5%-1.2%
Q4 2019+7.1%+3.0%-16.2%
Q3 2019+2.2%+7.9%-10.1%
Q2 2019+2.7%+6.8%+36.5%
Q1 2019-10.8%-17.2%-21.5%
Q4 2018-3.8%-2.9%-14.3%
Q3 2018-4.6%-7.6%-22.9%
Q2 2018+5.6%+7.8%+6.7%
Q1 2018+0.0%+8.7%+10.0%
Q4 2017-6.1%+0.0%+15.2%
Q3 2017-12.8%-10.6%-25.5%
Q2 2017-6.8%-11.4%-22.7%
Q1 2017-5.5%-5.5%+1.8%
Q4 2016-1.8%+16.1%-3.6%
Q3 2016-3.6%
Q2 2016+2.0%
Q1 2016-7.7%
Q4 2015-8.5%
Q3 2015+1.1%
Q2 2015+23.0%
Q1 2015+4.0%
Q4 2014-5.0%
Q3 2014-2.6%
Q2 2014-7.0%
Q1 2014+15.3%
Q4 2013-7.0%
Q3 2013+1.6%
Q2 2013-5.9%
Q1 2013+7.9%
Q4 2012-6.3%
Q4 2010-6.3%
Q3 2011+5.0%
Q3 2012+5.0%
Q2 2012-5.9%
Q2 2011-5.9%
Q1 2012-3.8%
Q1 2011-3.8%
Q4 2011-3.8%
Q3 2010-9.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro